Mayo Clinic Precure - Prospective Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Enrolling By Invitation
- Sponsor
- Mayo Clinic
- Enrollment
- 100,000
- Locations
- 1
- Primary Endpoint
- Build a comprehensive, multi-omics and phenotype dataset
Study Overview
Brief Summary
The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for disease therapy.
Participants will be asked to:
- collect biological samples,
- download a mobile app,
- collect speech (voice) recordings, and
- complete surveys
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age ≥ 18 years
- •Registered Mayo Clinic patient
- •Able to provide informed written consent
- •Able to receive mail and packages within a United States (US) state
- •Able to collect and ship samples within a US state via FedEx for overnight delivery
Exclusion Criteria
- •Active hematological cancer or history of a hematological cancer
- •Allogeneic Bone Marrow Transplant (autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
- •Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
Arms & Interventions
Suspected Genetic Predisposition or Multi-Omics Contribution
Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution
Health Control
Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.
Outcomes
Primary Outcomes
Build a comprehensive, multi-omics and phenotype dataset
Time Frame: Up to 5 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Konstantinos N. Lazaridis, M.D.
Executive Director, Center for Individualized Medicine
Mayo Clinic